Berberine on the Secretion of Incretin

NCT05947370 | Completed Early Phase 1

• 1 other identifier: BBR incretin
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 2

Brief Summary

Berberine (BBR) is the main active ingredient of the ancient Chinese herb medicine Coptis. The hypoglycemic effect of BBR has been demonstrated in numerous studies. Although BBR is safe and effective in the treatment of diabetes, its exact hypoglycemic mechanism is still unclear. Jin-Kui Yang found that BBR can promote GLP-1 secretion from intestinal L cells in mice in vitro and in vivo, thereby achieving the effect of lowering blood glucose, but it is still unknown whether BBR can promote incretin secretion in humans. In this study, investigators plan to examine the effect of BBR on secretion of incretin in human.

Conditions

Diabetes Mellitus

Outcome Measures

Primary Outcomes (3)

• Differences of serum GLP-1 levels between BBR and placebo treatment groups during the glucose tolerance test.

  To compare the mean serum GLP-1 in the two groups during glucose tolerance test.

  4 hours

• Differences of serum GIP levels between BBR and placebo treatment groups during the glucose tolerance test.

  To compare the mean serum GIP levels in the two groups during glucose tolerance test.

  4 hours

• Differences of blood glucose levels between BBR and placebo treatment groups during the glucose tolerance test.

  To compare the mean blood glucose levels in the two groups during glucose tolerance test.

  4 hours

Secondary Outcomes (6)

• Differences of serum insulin levels between BBR and placebo treatment groups during the glucose tolerance test.

  The time frame is the same as Primary Outcome Measure 1

• Differences of serum C-peptide levels between BBR and placebo treatment groups during the glucose tolerance test.

  4 hours

• Differences of serum potassium levels between BBR and placebo treatment groups during the glucose tolerance test.

  4 hours

• Differences of serum sodium levels between BBR and placebo treatment groups during the glucose tolerance test.

  4 hours

• Differences of serum chloride levels between BBR and placebo treatment groups during the glucose tolerance test.

  4 hours

Other Outcomes (2)

• Differences of heart rate between BBR and placebo treatment groups during the glucose tolerance test.

  4 hours

• Differences of QT-interval duration between BBR and placebo treatment groups during the glucose tolerance test.

  4 hours

Study Arms (2)

Berberine Chloride

EXPERIMENTAL

This study employed a randomized, double-blind, placebo-controlled, two-period crossover design: subjects were randomized into two groups of equal size. The random allocation was conducted by asking volunteers to select the randomized number generated by computer. Each number represented placebo or BBR, and each group has the same number of numbers. The dosing sequence in the first group was oral BBR in the first cycle and oral placebo in the second cycle. The second group was administered placebo in the first cycle and BBR in the second cycle. Take the second dose 14 days after the first dose. After the last dose, continue to observe for 14 days to watch for side effects. On each experimental day, after an overnight fast, the subjects received a single oral dose of 1 g of BBR or a corresponding dose of the placebo.

Drug: Berberine Chloride; Drug: Placebo

Placebo control

PLACEBO COMPARATOR

This study employed a randomized, double-blind, placebo-controlled, two-period crossover design: subjects were randomized into two groups of equal size. The random allocation was conducted by asking volunteers to select the randomized number generated by computer. Each number represented placebo or BBR, and each group has the same number of numbers. The dosing sequence in the first group was oral BBR in the first cycle and oral placebo in the second cycle. The second group was administered placebo in the first cycle and BBR in the second cycle. Take the second dose 14 days after the first dose. After the last dose, continue to observe for 14 days to watch for side effects. On each experimental day, after an overnight fast, the subjects received a single oral dose of 1 g of BBR or a corresponding dose of the placebo.

Drug: Berberine Chloride; Drug: Placebo

Interventions

Berberine Chloride DRUG

Traditional Chinese medicine

Berberine Chloride; Placebo control

Placebo DRUG

Placebo control

Berberine Chloride; Placebo control

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Voluntary participation in the trial and signed informed consent form.
• Healthy male subjects aged 18-45 years (including 18 and 45 years).
• No history of current or former diseases such as heart, liver, kidney, gastrointestinal tract, nervous system, respiratory system, mental disorders and metabolic abnormalities that the investigator considers meaningful; no physical examination, electrocardiogram, and laboratory examination results abnormality or abnormality has no clinical significance (subject to the judgment of the physician).
• Body mass index of 18.0-25.0 kg/cm2 (including 18.0 and 25.0 kg/cm2) and no centripetal obesity (waist-to-hip ratio less than 0.9).
• No family history of diabetes mellitus and obesity.
• Normal glucose tolerance (fasting blood glucose \<6.1 mmol/L and 2h blood glucose \<7.8mmol/L after oral administration of 75g glucose) and normal insulin secretion function (as judged by the investigator through the results of insulin release experiment).
• Able to communicate well with the investigator and complete the study in accordance with the study regulations.

You may not qualify if:

• Infection with hepatitis (A, B, or C), HIV and syphilis.
• Those with clear allergy to berberine hydrochloride or its preparation components; those with drug (including salicylic acid) allergy, history of allergic diseases or allergic constitution.
• Patients with hemolytic anemia and glucose-6-phosphate dehydrogenase deficiency.
• Those who have used any prescription medication, herbal medicine within 4 weeks prior to dosing and/or taken over-the-counter medication (except for subjects with occasional or restricted use of paracetamol), supplements (except for routine vitamin supplementation) within 2 weeks prior to dosing.
• Cumulative amount of blood loss (eg. blood donation) over 400mL within 3 months prior to baseline visit and during the study.
• Heavy smokers (25 or more cigarettes per day) and heavy drinkers (14 units of alcohol per week, 1 unit = 285ml of beer, or 25ml of spirits, or 100ml of wine).
• Those with a history of substance abuse or positive urine test for prohibited drugs.
• Those who participated in any clinical trial within 1 month prior to the trial, or those who plan to participate in other clinical trials during or within 1 month after the end of the trial.
• Other circumstances that the investigator considers unsuitable for participation in this study.

Sponsors & Collaborators

• Beijing Tongren Hospital: lead

Study Sites (2)

Beijing Tongren Hospital, Capital Medical University

Beijing, Beijing Municipality, 100730, China

Location

Hao Wang

Beijing, China

Location

Related Publications (2)

• Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81. doi: 10.1016/j.jep.2014.09.049. Epub 2014 Dec 10.

  PMID: 25498346 BACKGROUND

• Luthra A, Misra A. The marketing of unproven drugs for diabetes and dyslipidaemia in India. Lancet Diabetes Endocrinol. 2015 Oct;3(10):758-60. doi: 10.1016/S2213-8587(15)00328-9. No abstract available.

  PMID: 26386988 BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: June 4, 2023
• First Posted: July 17, 2023
• Study Start: October 12, 2022
• Primary Completion: April 6, 2023
• Study Completion: April 20, 2023
• Last Updated: July 17, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)